ADMP
$0.79
Adamis Pharmaceuticl
($.02)
(2.36%)
ADMP
Earnings Whisper ®
N/A
3rd Quarter September 2020
Consensus:  ($0.04)
Revenue:  $8.15 Mil
Monday
Nov 16
4:40 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when ADMP reports earnings?
Beat
Meet
Miss

Where is ADMP's stock price going from here?
Up
Flat
Down
Stock chart of ADMP
Analysts
Summary of analysts' recommendations for ADMP
Score
Grade
Pivots
Resistance
$0.85
$0.84
$0.81

$0.80

Support
$0.78
$0.76
$0.74
Tweet
Growth
Description
Adamis Pharmaceuticals Corporation, formerly Cellegy Pharmaceuticals, Inc., is a specialty pharmaceutical company engaged engages in the research, development, and commercialization of prescription medicines for the treatment of viral infections. Adamis Pharmaceuticals is composed of two wholly owned subsidiaries, Adamis Labs and Adamis Viral Therapies. Adamis Labs is a commercial stage specialty pharmaceutical company targeting high-prescribing physicians in the allergy, respiratory and pediatric medicine market segments. To complement and add to the sales efforts of Adamis Labs, Adamis Viral Therapies is focused on the development of patented, highly-valued proprietary vaccine technology that Adamis believes has the potential to prevent or treat infections such as influenza or chronic hepatitis. Adamis also provides packaging for pharmaceutical and nutraceutical products. The company is headquartered in Del Mar, California.
Peers
InterCeptRegeneron PharmaceuticalsVertex PharmaceuticalsBioMarin PharmaceuticalZoetisBristol-Myers SquibbJohnson & JohnsonMerck & Co.PfizerUltragenyx Pharmaceutical